🇺🇸 FDA
Pipeline program

Alogabat

BP41315

Phase 2 small_molecule completed

Quick answer

Alogabat for Angelman Syndrome is a Phase 2 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).

Program details

Company
Hoffmann-La Roche
Indication
Angelman Syndrome
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials